Dr. Julie Allickson
Board Member
Julie Allickson, PhD Director of the Regenerative Medicine Clinical Center at Wake Forest Institute for Regenerative Medicine has more than 27 years of experience in clinical translation of cellular therapies and regenerative medicine products including entrepreneurial and business management and board directorship experience.
Dr. Allickson has 8 years’ experience as an executive officer with a publicly traded company building services for cellular banking along with licensure of technology with more than 30 affiliates. An experienced scientist delivering innovation, driving milestones, maintain sensitivity to financial considerations, building high performance multidisciplinary teams, strategic planning, project management, and regulatory expertise. Dr. Allickson has a consistent history of creating value in clinical development and translation. Dr. Allickson heads the clinical translation team streamlining development to create a robust pipeline of products in early phase clinical trials and FDA registered products including cell therapy, tissue engineered organs and tissues, biomaterials and devices. Translation begins at Proof-of-Concept where early discussion with regulators and clinicians are critical in moving the technology from the bench to the bedside. Prior to the Institute Dr. Allickson was the Vice President of Research and Development and Laboratory Operations for Cryo-Cell International. Dr. Allickson was part of the team to perform the first Bone Marrow Transplant at the University of Miami in 1990. She has a Doctorate in Health Sciences along with a Master’s Degree in Medical Laboratory Sciences. She is one of the founding members of the International Society of Cellular Therapy in 1992 and has been a member of the American Association of Blood Banks (AABB) for 27 years. Dr. Allickson is on the Board of Directors for AABB, Vice Chair for Cord Blood Association Quality Committee, Technical Advisory Board for Tissue Engineered Products under ICCBBA and the ISCT Commercialization Committee.
Read more +
Dr. Laura de Girolamo
Board Member
Laura de Girolamo, PhD was born and grew up in Italy, where she received her MSc in Biology and Ph.D from the University of Milan. She worked at the Institute of Orthopaedics and Traumatology of the University of Milan, where she started to focus on cell treatments for cartilage and bone regeneration. She got her post-doctoral training between the Galeazzi Orthopaedic Institute and other international centers including the Cartilage Repair Center, Boston, MA affiliated with Brigham and Women's Hospital and Harvard Medical School.
She is currently the Director of the Orthopaedic Biotechnology Laboratory of the Galeazzi Orthopaedic Institute in Milan. Her basic and translational research focus is on mesenchymal stem cells, particularly derived from adipose tissue and tendons, and cell delivery systems. The goal of Dr. de Girolamo’s laboratory is to derive biological solutions aimed to promote cartilage, tendon and bone regeneration by improving activity and clinical therapeutic potential of MSCs. Her clinical research activity includes the study of cell-based products and growth factors directly derived in surgery room. She served as PI or co-PI in several research projects collaborating with national and international research centers. She is author of more than 50 papers and of 7 book chapters in orthopedic regenerative medicine, and has been speaker at more than 150 national and international congresses and courses. She is Chair of the Basic Science Committee of the European Society of Sports Traumatology Knee Surgery and Arthroscopy (ESSKA) and Chair of the Research Committee of Italian Knee Surgery Arthroscopy Sports and Cartilage Society (SIGASCOT). She was co-founder of the Italian Mesenchymal Stem Cell Group (GISM) and currently member of its Executive Committee.
Read More +
Dr. Peter Johnson
Board Chairman
Peter C. Johnson, MD is a University of Notre Dame and SUNY Upstate Medical University graduate. After General and Plastic Surgery training, Dr. Johnson practiced reconstructive surgery for ten years at U. Pittsburgh where he founded and was the first President of the Pittsburgh Tissue Engineering Initiative.
Subsequent roles were co-founder/CEO of Tissue Informatics, EVP of Life Sciences, CMO and CBO of Icoria, EVP, Entegrion, Inc. and VP, Research and Development and Medical and Scientific Affairs of Vancive Medical Technologies, an Avery Dennison business. He presently serves as President and CEO of Scintellix, LLC, Chief Medical Advisor to Vancive Medical Technologies and Co-Founding Principal of MedSurgPI, LLC. He has Chaired the Plastic Surgery Research Council, was President of the Pennsylvania Biotechnology Association and the Tissue Engineering Society, International (now TERMIS) and is presently the Co-Editor-in-Chief of the three-part Journal, Tissue Engineering. He serves on the board of the Transverse Myelitis Association and is on the Industry Advisory Board of the UNC/NC State Joint Program in Bioengineering. He is an Adjunct Professor of Surgery, Bioengineering and Business at the University of North Carolina at Chapel Hill, of Bioengineering at NC State and of Regenerative Medicine at Wake Forest University School of Medicine. He is an avid cook; fly fisherman, artist, novelist and farmer.
Read More+
Dr. Wenchun Qu
Board Member
Wenchun Qu is board certified in Physical Medicine and Rehabilitation (PMR), Pain Medicine, and Regenerative Medicine. He is the Director of Regenerative Pain Medicine, Research Committee Chair of Spine Center, a Consultant at Department of PMR and Division of Pain Medicine at Mayo Clinic, Rochester, Minnesota.
He is an assistant professor of PMR at Mayo College of Medicine. Dr. Qu earned his medical degree from Second Military Medical University in Shanghai, China, a PhD in Occupational Science and a MS in Biostatistics at University of Southern California, Los Angeles, California. He completed residency in PMR and fellowship in Pain Medicine at Mayo Clinic Rochester, and postdoctoral fellowship training at University of Pennsylvania. His clinical interests are regenerative therapy for degenerative spine and musculoskeletal conditions, interventional pain medicine, and musculoskeletal ultrasound medicine. His research is primarily focused on stem cell therapy for spine and musculoskeletal conditions, and outcome measure studies in pain medicine. Dr. Qu has more than 30 scientific publications and has won Best Basic Science Research Award of Spine Intervention Society, Best Abstract Award of American Academy of Pain Medicine, and Best of Meeting Award of American Society of Regional Anesthesia and Pain Medicine. He is currently supported by funding in the amount of 1 million USD from US Department of Defense, Korean Ministry of Health, Industry, and multiple intramural funding mechanisms. He currently serves on the Board of Directors and Scientific Advisory Board of the American Academy and Board of Regenerative Medicine, Board of Directors of Society of Chinese American Physician Entrepreneurs, Research Committee of Association of Academic Physiatrists, Committee of International Education of Spine Intervention Society, and as Conference Chairman of Boston BioLife Hands-on Stem Cell Workshop. He is a member of multiple regenerative medicine, PMR, and pain societies. He serves on the editorial board and as reviewers of multiple peer-reviewed journals. In the past, he served as the president and the director of board of the American Association of Chinese Rehabilitation Physicians.
Read More +
Dr. Massimo Dominici
Board Member
Biosk. Massimo Dominici (Jan 2017) Massimo Dominici is a 44 years-old clinical scientist developing cell and gene therapy approaches around cancer patients. He got his MD degree at the University of Pavia (Italy) then internship, residency and post-doctoral training between the Institute of Haematology, Vienna University (Austria), the Division of Immuno-haematology, Ferrara University (Italy)
St Jude Children's Hospital, Memphis (USA). Then hospital physician, Associate Professor of Medical Oncology, Head of the Laboratory of Cellular Therapies, Director of the residency school in medical oncology at the University of Modena and Reggio Emilia (Modena, Italy). 26 between research grants and awards for more than 6,6M euro. More than 120 papers published or in press on stem cells, tissue regeneration, experimental oncology and hematology with over 12500 citations, H-index: 32. Author of 3 books, 3 chapters and 7 patents. Scientific founder of the University start-up Rigenerand that recently recieved a 8,7M euro of first round of financing. Founder and scientific coordinator of the Mirandola Science & Tecnology Park. Co-editor, editorial board member and referee for over 50 scientific Journals. Referee for 16 national & international founding Bodies. He has been co-founder of the Forum of Italian Researcher on MSC (FIRST), board member of JACIE, WBMT and advisor for the Italian Minister of Health. He has been member of International Society for Cellular Therapy (ISCT), ASH, ESCGT, IFATS, IPLASS. He has been President of ISCT 2014-2016, now Chair of the ISCT advisory board and Chair of the ISCT presidential task-force on unproven cellular therapy.
Read More +
Dr. Diego Correa
Board member
Diego Correa, MD, MSc, PhD M.D. from Universidad Javeriana (Bogotá - Colombia); M.Sc. in Mechanical Engineering from Universidad de Los Andes (Bogotá - Colombia) obtaining the Engineering School Fellowship for academic and research excellence; Ph.D. in Cellular and Molecular Physiology from Yale University/Harvard University where he received a full scholarship.
A recipient of the George Robert Pfeiffer Fellowship from the Gustavus and Louise Pfeiffer Research Foundation. In 2009, he joined the laboratory of Professor Arnold Caplan at the Skeletal Research Center - Case Western Reserve University (Cleveland, OH), where he led the projects related with the Biology of adult Mesenchymal Stem Cells (MSCs) and their use in the areas of Articular Cartilage Tissue Engineering, and the description of their role as gatekeepers controlling the process of distant Cancer Metastasis. Currently holds a joint appointment as Assistant Professor between the Department of Orthopaedics (Division of Sports Medicine) and the Diabetes Research Institute at the University of Miami, Miller School of Medicine. Dr. Correa’s laboratory focuses on the Biology of Mesenchymal Stem Cells (MSCs), including the identification of functional subpopulations of cells, their immunomodulatory and trophic activities, intercellular communication through exosomes, and their potential therapeutic application during islet cell transplantation in type 1 Diabetes and in joint diseases, using both in vitro and in vivo models. In addition, he holds an Adjunct Assistant Professor appointment at the Dept. of Biology, Skeletal Research Center - Case Western Reserve University, where he continues interacting with Professor Arnold Caplan participating in various research areas and funded projects. Dr. Correa is an expert in Cell Biology, with special emphasis on MSC biology and clinical applications in Regenerative Medicine. Throughout his career, Dr. Correa has approached Medicine and Science in a dynamic multidisciplinary manner, using tissue injury and regeneration, and the musculoskeletal system as primary platforms. He has analyzed them from various perspectives, including a clinical view of tissue damage in skeletal diseases, an engineering analysis of tissue mechanics, a basic science study of the cellular and molecular underpinnings of skeletal development using genetic models, and the development of novel therapeutic approaches to treat immune-related conditions and traumatic skeletal diseases based on stem cell therapy. This cohesive work has been recognized by distinctions such as the Young Investigator Award from OARSI (Osteoarthritis Research Society International) and chosen as special delegate for the Academy of Achievements 46th International Summit (Washington DC). He holds various patents submissions; is author and co-author of a significant number of scientific publications in recognized journals; serves on the editorial board and as peer reviewer of various recognized scientific journals; serves as formal reviewer for scientific institutions both nationally (e.g.: CIRM) and internationally (National Medical Research Council of Singapore); and is an invited speaker and lecturer in national and international scientific and medical meetings. Dr. Correa also participates in diverse entrepreneurial activities, such as the creation and evaluation of private start-up companies in the areas of Regenerative Medicine and adult stem cell-based therapy. He also participates in various Scientific Advisory Boards in companies within the Regenerative Medicine field.
Read More +
Dr. David Harrell
Board Member
David Harrell, PhD, DABRM, FAARM, FRSPH David Harrell, Owner of Harrell Bioscience Consulting, has two decades of experience in basic science research, translational research into clinical practice, strategic planning, innovation, technology development, and executive management. Dr. Harrell has ties in government, industry, and academia.
Dr. Harrell focuses his efforts on translational research and clinical development and application of basic science. In this focus area, he works with granting agencies, regulatory bodies (e.g., US Food and Drug Administration, European Medicines Agency), and government officials to bring technologies from the research bench to the clinic bedside. Dr. Harrell is one of the founding members of the American Academy and Board of Regenerative Medicine (AABRM) and is the current the President of the AABRM; he is also the Editor-In-Chief of the Journal of the American Academy of Regenerative Medicine. Additionally, Dr. Harrell is Affiliated Research Scientist at BioScience Research Associates; formally the Center for Blood Research Laboratories which originated as CBR Biomedical Research Institute (now know as the Immune Disease Institute) and is affiliated academically with Harvard Medical School. Dr. Harrell also serves on the Multidisciplinary Neuroscience Alliance at the University of Central Florida College of Medicine. Dr. Harrell is a Diplomat of the American Board of Regenerative Medicine and Fellow of the American Academy of Regenerative Medicine as well as Fellow of the Royal Society of Public Health. Dr. Harrell has served as the Chief Scientific Officer/Chief Scientist for NuroStar, Philips/Respironics, Harvest-Terumo, and RMTI; additionally he has been Adjunct Assistant Professor at MSNI and UCF College of Medicine. Dr. Harrell has received numerous national and international awards for his basic science and translational research and given over 50 Keynote Presentations with several of those being on topics never previously discussed.
Read More+
Dr. Annu Navani
Board Member
Dr. Annu Navani, MD is the Founder and CEO of Comprehensive Spine and Sports Center, the leader in interventional and interdisciplinary spine and orthopedic care. She founded Comprehensive Spine and Sports Center in 2008 with the vision of bringing evidence-based, cutting-edge therapies to the community and since then has grown her office locations to Campbell, Fremont, Morgan Hill and Modesto where she offers conventional and regenerative medicine therapies along with her team of interdisciplinary medical providers.She takes pride in staying on the forefront of interventional orthopedic and spine procedures while serving as an international thought leader in Regenerative Medicine.
Dr. Navani is an Adjunct Clinical Associate Professor at Division of Pain, Stanford University School of Medicine. Dr. Navani completed her Anesthesiology residency from Medical College of Wisconsin, Milwaukee and fellowship in Pain Medicine from the University of California, Davis. She is board certified in Anesthesiology and Pain Medicine by American Board of Anesthesiology and in Interventional Pain by American Board of Interventional Pain Physicians. She is widely published in the field of Regenerative Medicine and has contributed via several peer reviewed journal articles, visionary editorials and book chapters. She is well recognized as an eloquent speaker at both national and international platforms having shared her vision of future of biologics and tissue engineering in most continents. Her clinical and research activities involve spine and orthopedic biologics with special interest in application of biologic therapies for restoration of structure and function of disrupted discs. She sits on the board of American Society of Interventional Pain Physicians (ASIPP) and Chairs the ASIPP Regenerative Medicine activities. She is the member of Editorial board of the journal, Pain Physician as well as board member of the California Society of Industrial Medicine and Surgery and a Trustee and Past President of the American Association of Physicians of Indian origin. She is the recipient of the Outstanding Achievement Award from the American Association of Interventional Pain Physicians, The Exceptional Effort and Dedication award from The American Association of Physicians of Indian Origin as well as The Honorable Mention Award from the Postgraduate assembly in Anesthesiology. Her vision is to forward the field of regenerative medicine by rigorous research in biomedical engineering and cellular regeneration in an effort to offer it as a standard treatment to create a functional and fulfilling life for people.
Read More +
Dr. Stephen Mannis
Board Member
Dr. Stephen Mannis received his Bachelor of Science degree at Stanford University and his M.D. degree at the University of California, San Diego. He is board certified in both Internal Medicine and Anesthesiology. He also holds an MBA degree which he received from the University of South Florida.
He has held leadership positions in large physician organizations and currently serves as Medical Director of 2 large ambulatory surgery centers in Sacramento and is a managing director of a physician group with an ownership interest in a multispecialty surgery center. He also holds a faculty position teaching in the Department of Anesthesiology and Pain Medicine at the University of California, Davis. He has keen interest in the emerging field of regenerative medicine and is a member of the International Federation of Adipose and Therapeutics and Science.
Read more +
Dr. Dmitry Shvartsman
Board Member
Dmitry Shvartsman, PhD biography Dr. Dmitry (Dima) Shvartsman was born in Kharkov (Ukraine) and graduated (PhD in Neurobiology, 2008) from Tel Aviv University Life Sciences Faculty (Israel), focusing his studies on the biophysical properties of the cell plasma membrane and dynamics of interactions between membrane proteins and membrane domains. He received the Long-Term Postdoctoral Fellowship form the European Molecular Biology Organization (EMBO) to conduct his postdoctoral studies in Cell and Tissue Engineering laboratory at Harvard University.
His research in biomedical engineering and tissue regeneration at Harvard University School of Engineering and Applied Sciences (SEAS) was focused on understanding the biological mechanisms of tissue regeneration, utilizing the sustained and local delivery of growth factors and cells, developing models of cell interactions in 3D modeling devices, microfluidic systems and designing novel tools for the plastic and restorative surgery, with leading plastic surgery teams in Harvard Medical School and Brigham Women’s Hospital in Boston. His broad interdisciplinary training and scientific background are combined with business development education, obtained through Harvard Business School courses and patent reviews for Harvard Office of Technological Development. After additional training at Brigham Women’s Hospital in Boston and Harvard Medical School, in Laboratory of Nanomedicine and Biomaterials, Dmitry has joined Harvard Stem Cell Institute (HSCI) in Cambridge as Senior Research Manager, working in field of regenerative biology and stem cell development. He leads both technical team and students at HSCI, focusing his research at stem cell differentiation toward endocrine lineages for curing juvenile diabetes patients. Dmitry is an author of 20 peer-reviewed articles, 2 chapters in books and 1 issued patent. He is a co-founder of Rethink Pharmaceuticals bioinformatical start-up company (Israel). He is the member of Biomedical Engineering Society (BMES), American Association for the Advancement of Science (AAAS), Tissue Engineering International and Regenerative Medicine Society (TERMIS) and the American Society for Cell Biology (ASCB).
Read More +